Neogen Corporation (NEOG) Gross Margin
- Gross margin · 12 months: Value 46.93%; Formula and calculation Gross profit / revenue. Period ending 2026-05-31..
Gross margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 46.93% | Gross profit / revenue. Period ending 2026-05-31. $408.50M ÷ $870.40M × 100 ≈ 46.93% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 408.50M USD | Gross Profit |
| Revenue | 870.40M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 461.90M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-05-31 | $408.50M | $870.40M | $461.90M | 46.93% |
| 2026-02-28 | $393.58M | $870.56M | $476.99M | 45.21% |
| 2025-11-30 | $404.77M | $880.32M | $475.55M | 45.98% |
| 2025-08-31 | $411.42M | $886.89M | $475.47M | 46.39% |
| 2025-05-31 | $421.38M | $894.66M | $473.29M | 47.10% |
| 2025-02-28 | $442.00M | $906.00M | $463.99M | 48.79% |
| 2024-11-30 | $448.62M | $913.83M | $465.21M | 49.09% |
| 2024-08-31 | $452.06M | $912.20M | $460.13M | 49.56% |
| 2024-05-31 | $463.90M | $924.22M | $460.32M | 50.19% |
| 2024-02-29 | $473.60M | $929.24M | $455.64M | 50.97% |
| 2023-11-30 | $464.68M | $918.68M | $454.00M | 50.58% |
| 2023-08-31 | $460.45M | $919.09M | $458.64M | 50.10% |
| 2023-05-31 | $405.95M | $822.45M | $416.49M | 49.36% |
| 2023-02-28 | $347.77M | $720.73M | $372.96M | 48.25% |
| 2022-11-30 | $297.22M | $630.72M | $333.50M | 47.12% |
| 2022-08-31 | $245.28M | $531.20M | $285.93M | 46.17% |
| 2022-05-31 | $243.01M | $527.16M | $284.15M | 46.10% |
| 2022-02-28 | $235.71M | $514.49M | $278.79M | 45.81% |
| 2021-11-30 | $232.14M | $502.96M | $270.81M | 46.16% |
| 2021-08-31 | $224.76M | $487.44M | $262.68M | 46.11% |
| 2021-05-31 | $215.06M | $468.46M | $253.40M | 45.91% |
| 2021-02-28 | $209.09M | $450.11M | $241.01M | 46.45% |
| 2020-11-30 | $200.57M | $433.27M | $232.69M | 46.29% |
| 2020-08-31 | $198.39M | $426.07M | $227.68M | 46.56% |
| 2020-05-31 | $196.28M | $418.17M | $221.89M | 46.94% |
| 2020-02-29 | $195.08M | $418.86M | $223.78M | 46.57% |
| 2019-11-30 | $194.38M | $416.69M | $222.31M | 46.65% |
| 2019-08-31 | $193.38M | $415.98M | $222.60M | 46.49% |
| 2019-05-31 | $191.92M | $414.19M | $222.27M | 46.34% |
| 2019-02-28 | $189.89M | $412.54M | $222.66M | 46.03% |
| 2018-11-30 | $189.86M | $409.75M | $219.89M | 46.34% |
| 2018-08-31 | $188.06M | $403.33M | $215.27M | 46.63% |
| 2018-05-31 | $190.25M | $402.25M | $212.00M | 47.30% |
| 2018-02-28 | $187.68M | $391.81M | (m) | 47.90% |
| 2017-11-30 | $183.04M | $384.31M | (m) | 47.63% |
| 2017-08-31 | $177.36M | $373.20M | (m) | 47.52% |
| 2017-05-31 | $171.97M | $361.59M | (m) | 47.56% |
| 2017-02-28 | $166.80M | $352.83M | (m) | 47.28% |
| 2016-11-30 | $161.12M | $341.17M | (m) | 47.23% |
| 2016-08-31 | $155.75M | $330.06M | (m) | 47.19% |
| 2016-05-31 | $153.06M | $321.27M | (m) | 47.64% |
| 2016-02-29 | $148.91M | $309.81M | (m) | 48.07% |
| 2015-11-30 | $147.42M | $301.49M | (m) | 48.90% |
| 2015-08-31 | $143.40M | $290.33M | (m) | 49.39% |
| 2015-05-31 | $139.69M | $283.07M | (m) | 49.35% |
| 2015-02-28 | $134.03M | $271.73M | (m) | 49.32% |
| 2014-11-30 | $131.03M | $265.31M | (m) | 49.39% |
| 2014-08-31 | $126.31M | $256.46M | (m) | 49.25% |
| 2014-05-31 | $122.60M | $247.41M | (m) | 49.55% |
| 2014-02-28 | $118.94M | $236.15M | (m) | 50.37% |
| 2013-11-30 | $115.55M | $225.21M | (m) | 51.31% |
| 2013-08-31 | $113.36M | $216.35M | (m) | 52.40% |
| 2013-05-31 | $109.49M | $207.53M | (m) | 52.76% |
| 2013-02-28 | $105.01M | $200.07M | (m) | 52.49% |
| 2012-11-30 | $100.59M | $193.93M | (m) | 51.87% |
| 2012-08-31 | $95.94M | $188.08M | (m) | 51.01% |
| 2012-05-31 | $92.42M | $184.05M | (m) | 50.22% |
| 2012-02-29 | (m) | (m) | (m) | (m) |
| 2011-11-30 | (m) | (m) | (m) | (m) |
| 2011-08-31 | (m) | (m) | (m) | (m) |
| 2011-05-31 | $87.79M | $172.68M | (m) | 50.84% |
| 2011-02-28 | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | (m) | (m) |
| 2010-05-31 | $72.97M | $140.51M | (m) | 51.94% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |